Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients

K. C. Huang, C. C. Yang, S. P. Hsu, K. T. Lee, H. W. Liu, S. Morisawa, K. Otsubo, C. T. Chien

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n = 15) or with vitamin C (VC)- (n = 15), vitamin E (VE)-coated dialyzer (n = 15), or ERW treatment (n = 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H2O 2, after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC> ERW> VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.

Original languageEnglish
Pages (from-to)391-398
Number of pages8
JournalKidney International
Volume70
Issue number2
DOIs
Publication statusPublished - 2006 Jul 7

Fingerprint

Chronic Kidney Failure
Renal Dialysis
Erythrocytes
Electrolytes
Water
Cytochrome-B(5) Reductase
Methemoglobin
Ascorbic Acid
Water Purification
Oxidative Stress
Cytokines
Hemolysis
Vitamin E
Antioxidants
Oxalates
Hematocrit
Lipid Peroxidation
Anemia
Reactive Oxygen Species
Cell Survival

Keywords

  • Electrolyzed-reduced water
  • Hemodialysis
  • Hemolysis
  • Oxidative stress

ASJC Scopus subject areas

  • Nephrology

Cite this

Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients. / Huang, K. C.; Yang, C. C.; Hsu, S. P.; Lee, K. T.; Liu, H. W.; Morisawa, S.; Otsubo, K.; Chien, C. T.

In: Kidney International, Vol. 70, No. 2, 07.07.2006, p. 391-398.

Research output: Contribution to journalArticle

Huang, K. C. ; Yang, C. C. ; Hsu, S. P. ; Lee, K. T. ; Liu, H. W. ; Morisawa, S. ; Otsubo, K. ; Chien, C. T. / Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients. In: Kidney International. 2006 ; Vol. 70, No. 2. pp. 391-398.
@article{358f403b926b4a0b9a09955886169604,
title = "Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients",
abstract = "Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n = 15) or with vitamin C (VC)- (n = 15), vitamin E (VE)-coated dialyzer (n = 15), or ERW treatment (n = 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H2O 2, after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC> ERW> VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.",
keywords = "Electrolyzed-reduced water, Hemodialysis, Hemolysis, Oxidative stress",
author = "Huang, {K. C.} and Yang, {C. C.} and Hsu, {S. P.} and Lee, {K. T.} and Liu, {H. W.} and S. Morisawa and K. Otsubo and Chien, {C. T.}",
year = "2006",
month = "7",
day = "7",
doi = "10.1038/sj.ki.5001576",
language = "English",
volume = "70",
pages = "391--398",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients

AU - Huang, K. C.

AU - Yang, C. C.

AU - Hsu, S. P.

AU - Lee, K. T.

AU - Liu, H. W.

AU - Morisawa, S.

AU - Otsubo, K.

AU - Chien, C. T.

PY - 2006/7/7

Y1 - 2006/7/7

N2 - Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n = 15) or with vitamin C (VC)- (n = 15), vitamin E (VE)-coated dialyzer (n = 15), or ERW treatment (n = 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H2O 2, after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC> ERW> VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.

AB - Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n = 15) or with vitamin C (VC)- (n = 15), vitamin E (VE)-coated dialyzer (n = 15), or ERW treatment (n = 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H2O 2, after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC> ERW> VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.

KW - Electrolyzed-reduced water

KW - Hemodialysis

KW - Hemolysis

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=33746132354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746132354&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5001576

DO - 10.1038/sj.ki.5001576

M3 - Article

C2 - 16760903

AN - SCOPUS:33746132354

VL - 70

SP - 391

EP - 398

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -